A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years
Latest Information Update: 10 Jun 2025
At a glance
- Drugs SP 0218 (Primary)
- Indications Yellow fever
- Focus Adverse reactions; Registrational
- Sponsors Sanofi
Most Recent Events
- 10 Jun 2025 New trial record